Palifermin (keratinocyte growth factor, KGF) is the prototype of an anti-mucositis drug and was first shown to reduce the duration and severity of oral mucositis after intensive chemotherapy and radiotherapy for hematologic cancers [101]. The gene discussed is FGF7; the disease is hematopoietic and lymphoid cell neoplasm.